By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genentech 

1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000


SEARCH JOBS
Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:
http://www.youtube.com/genentech#p/u/1/GJH4X5gxxf0

Connect with us via Social Media:

Facebook: www.facebook.com/GenentechJobs

Twitter: www.twitter.com/GenentechJobs

LinkedIn: www.linkedin.com/company/genentech





Key Statistics


Email:
Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY
 



Industry
Biotechnology

Segment
Biotherapeutics





Company News
Epizyme (EPZM), Genentech (RHHBY) Join Forces for Tazemetostat and Tecentriq Trial in Non-Hodgkin Lymphoma 6/23/2016 7:09:08 AM
Genentech (RHHBY), OSI Pharma (OSIP) to Fork Over $67 Million for Misleading Info About Cancer Drug Efficacy 6/7/2016 6:51:31 AM
Phase III Study Shows Genentech (RHHBY)’s Actemra (Tocilizumab) Maintained Steroid-Free Remission In People With Giant Cell Arteritis (GCA) 6/6/2016 2:49:11 PM
ASCO2016: Genentech (RHHBY)'s TECENTRIQ Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer 6/6/2016 7:10:05 AM
Genentech (RHHBY)'s Arthritis Med Actemra Successful In Late-Stage Study in Rare Artery Inflammation 6/6/2016 6:39:17 AM
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study 5/27/2016 5:42:32 AM
Evotec AG (EVTG.F) Extends Integrated Drug Discovery Alliance With Genentech (RHHBY) 5/24/2016 10:42:05 AM
Nine Bay Area Biotechs Vie to be the “Next Genentech (RHHBY)” 5/24/2016 6:33:42 AM
Another Healthcare Provider Accuses Genentech (RHHBY) of Fudging the Amount of Herceptin in Each Vial 5/23/2016 7:09:25 AM
Phase III Study Of Genentech (RHHBY)’s Alecensa (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer 5/19/2016 7:30:52 AM
12345678910...
//-->